Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Changes in methadone take-home dosing before and after COVID-19
Ofer Amram, Solmaz Amiri, Emily Thorn, et al.
Journal of Substance Abuse Treatment (2021) Vol. 133, pp. 108552-108552
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic
Christopher M. Jones, Carla Shoff, Kevin Hodges, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 10, pp. 981-981
Open Access | Times Cited: 108
Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy
Noa Krawczyk, Bianca Rivera, Emily Levin, et al.
The Lancet Public Health (2023) Vol. 8, Iss. 3, pp. e238-e246
Open Access | Times Cited: 57
Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives
Shoshana V. Aronowitz, Eden Engel‐Rebitzer, Abby Dolan, et al.
Harm Reduction Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 54
“The Idea is to Help People Achieve Greater Success and Liberty”: A Qualitative Study of Expanded Methadone Take-Home access in Opioid use Disorder Treatment
Leslie W. Suen, Stacy Castellanos, Neena Joshi, et al.
Substance Abuse (2022) Vol. 43, Iss. 1, pp. 1147-1154
Open Access | Times Cited: 36
Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder
Paul J. Joudrey, Marynia Kolak, Qinyun Lin, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e227028-e227028
Open Access | Times Cited: 33
Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis
Sophie A. Kitchen, Tonya Campbell, Siyu Men, et al.
International Journal of Drug Policy (2022) Vol. 103, pp. 103644-103644
Open Access | Times Cited: 30
Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic
Alyssa Shell Tilhou, Laura Dague, Brendan Saloner, et al.
JAMA Health Forum (2022) Vol. 3, Iss. 3, pp. e220093-e220093
Open Access | Times Cited: 27
Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations
Christopher Welsh, Suzanne Doyon, Katherine Hart
International Journal of Drug Policy (2022) Vol. 102, pp. 103591-103591
Open Access | Times Cited: 26
Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report
Paul J. Joudrey, Gavin Bart, Robert K. Brooner, et al.
Substance Abuse (2021) Vol. 42, Iss. 3, pp. 245-254
Open Access | Times Cited: 31
Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
Zachary Bouck, Ayden I. Scheim, Tara Gomes, et al.
International Journal of Drug Policy (2022) Vol. 104, pp. 103680-103680
Open Access | Times Cited: 20
Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic
Annie Y. Chen, David Powell, Bradley D. Stein
JAMA Network Open (2022) Vol. 5, Iss. 7, pp. e2223708-e2223708
Open Access | Times Cited: 17
Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety
Brendan Saloner, Penn Whitley, Eric Dawson, et al.
Addiction (2023) Vol. 118, Iss. 8, pp. 1549-1556
Open Access | Times Cited: 10
Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review
Victoria Panwala, Paul J. Joudrey, Melanie Kowalski, et al.
Journal of Substance Use and Addiction Treatment (2023) Vol. 152, pp. 209086-209086
Open Access | Times Cited: 10
State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID‐19 onset
Ignacio Bórquez, Arthur Robin Williams, Mei‐Chen Hu, et al.
Addiction (2025)
Closed Access
Comparative effectiveness of methadone take-home dose initiation in British Columbia, Canada: protocol for a population-based retrospective cohort study using target trial guidelines
Md. Belal Hossain, Brenda Carolina Guerra‐Alejos, Megan Kurz, et al.
BMJ Open (2025) Vol. 15, Iss. 3, pp. e095198-e095198
Open Access
Cultural attunement approach for enhanced uptake of harm reduction services: A qualitative study in marginalized U.S. communities
Lauretta Ekanem Omale, Judah Viola
Journal of Prevention & Intervention in the Community (2025), pp. 1-28
Closed Access
Medication-Assisted Treatment in Problem-solving Courts: A National Survey of State and Local Court Coordinators
Fanni Faragó, Thomas R. Blue, Lindsay Smith, et al.
Journal of Drug Issues (2022) Vol. 53, Iss. 2, pp. 296-320
Open Access | Times Cited: 16
Strategies to Improve Access to Care for Patients With Opioid Use Disorder
Ligang Liu, Chen Zhang, Andrea E. Bonny, et al.
Annals of Pharmacotherapy (2024)
Closed Access | Times Cited: 3
Illicit Substance Use and the COVID-19 Pandemic in the United States: A Scoping Review and Characterization of Research Evidence in Unprecedented Times
Anh Truc Vo, Thomas Patton, Amy Peacock, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 14, pp. 8883-8883
Open Access | Times Cited: 13
Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic
Kevin A. Hallgren, James Darnton, Sean Soth, et al.
Journal of Substance Abuse Treatment (2022) Vol. 143, pp. 108896-108896
Open Access | Times Cited: 13
The Impact of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on Substance Use in the United States
Jennifer A. Ross, Patrice Malone, Sharon Levy
Clinical Infectious Diseases (2022) Vol. 75, Iss. Supplement_1, pp. S81-S85
Open Access | Times Cited: 12
Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review
Cayley Russell, Jenna Ashley, Farihah Ali, et al.
International Journal of Drug Policy (2024) Vol. 127, pp. 104343-104343
Open Access | Times Cited: 2
“Sign Me Up”: a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic
James Darnton, Elenore P. Bhatraju, Kristin Beima‐Sofie, et al.
Addiction Science & Clinical Practice (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 5
Opioid agonist treatment in transition: A cross-country comparison between Austria, Germany and Switzerland
Tanja Schwarz, Judith Anzenberger, Martin Busch, et al.
Drug and Alcohol Dependence (2023) Vol. 254, pp. 111036-111036
Open Access | Times Cited: 5
Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids
Victoria Panwala, Emily Thorn, Solmaz Amiri, et al.
The American Journal of Drug and Alcohol Abuse (2023) Vol. 49, Iss. 5, pp. 597-605
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top